Kiora Pharmaceuticals has secured exclusive development and commercialization rights outside Asia to KIO-401 (mitucapistat), an investigational oral neuroprotective treatment for central retinal artery occlusion (CRAO), following promising Phase 2 and Phase 3 clinical results in Japan.
Announced in October, the licensing agreement with Senju Pharmaceutical will see Kiora advance the treatment into a multinational Phase 3 registration trial, targeted to begin in 2027. The company also intends to investigate KIO-401 as a potential treatment for non-arteritic anterior ischemic optic neuropathy (NAION).
KIO-401 is an oral small-molecule inhibitor of activated calpain, a calcium-dependent protease implicated in cellular injury following ischemia. By inhibiting calpain activation, the therapy aims to reduce downstream retinal damage and preserve visual function.
In a randomized Phase 2a study conducted in Japan, KIO-401 demonstrated statistically significant improvements in Early Treatment Diabetic Retinopathy Study visual acuity compared with a prospective observational registry.
A subsequent randomized, double-masked Phase 3 trial demonstrated improvements in best-corrected visual acuity, including statistically significant benefits among patients classified as legally blind at baseline under World Health Organization criteria.
Building on these findings, Kiora plans to conduct a larger, randomized, double-masked, controlled Phase 3 trial involving more than 100 patients with acute CRAO. The final study design will be determined following regulatory discussions, with initiation dependent on financing and regulatory alignment.
“An effective oral treatment could galvanize systems of care for acute CRAO recognition and management and expand treatment access to patients in regional and community hospitals,” said Brian Mac Grory, the associate professor of neurology and ophthalmology at Duke University School of Medicine, North Carolina, who led the development of the American Heart Association (AHA) scientific statement on CRAO management. "The reported clinical trial outcomes are the first encouraging results for a neuroprotective drug for CRAO and strongly support further evaluation of KIO-401."
Kiora also plans to initiate a Phase 2b trial in NAION in 2028, based on the shared mechanisms of ischemia-related cellular injury underlying both conditions. The company is additionally exploring potential applications in glaucoma, although further preclinical and clinical investigation would be required for this.
Under the licensing agreement, Kiora will pay Senju $3.5 million upfront, with further milestone payments and royalties tied to development and commercialization.
"We have an established relationship with Senju through our KIO-301 partnership, which facilitated our partnership on KIO-401. After reviewing results from Senju's previous work, we identified KIO-401 as a compelling late-stage asset,” explained the President and Chief Executive Officer of Kiora, Brian M. Strem. “We believe KIO-401 has the potential to meaningfully improve patient outcomes and achieve significant commercial value in the US, Europe, and other regions."
Source: Kiora Pharmaceuticals.